26 Nanoparticles and the Immune Stystem

Wednesday, Stream 1 l, 13.15 – 15.00
26. Nanoparticles and the Immune System

Session established in collaboration with the German Research Foundation (DFG) “Collaborative Research Center on Nanodimensional Polymer Therapeutics for Tumor Therapy” (CRC 1066), Johannes Gutenberg University, Mainz (D)
Nanoparticle carriers allow to change the biodistribution of their cargo, making it possible to target specific cells and tissues, as well as the immune system or to exclude others. This opens the possibility to steer a complex immune response by targeting key players and to induce an immunological treatment of cancer, to enhance antiviral vaccination or reduce unwanted autoimmune and allergic reactions. To this end, nanocarriers allow a co-delivery of active compounds further modifying the response.
Chair Prof. Dr. med. Volker Mailänder, Center for Translational Nanomedicine, University Medicine of the Johannes‐Gutenberg University Mainz (D) and Prof. Dr. med. Stephan Grabbe, Director of the Department of Dermatology, Medical Center & Polyclinic, Speaker of the Research Center for Immunotherapy, Mainz (D)
Complement Modulation of Nanomedicine Performance in Health and Disease
Prof. Dr. Moein Moghimi, Professor of Pharmaceutics and Nanomedicine, School of Pharmacy, Newcastle University, Translational and Clinical Research Institute, Faculty of Health and Medical Sciences, Newcastle University (UK), and Adjoint Professor, University of Colorado Medical Center, Denver, CO (USA)

Role of the Protein Corona in Nanoparticle Uptake by Immune Cells
Prof. Dr. med. Volker Mailänder, Center for Translational Nanomedicine, University Medicine of the Johannes‐Gutenberg University Mainz (D)

Modulation of Macrophage Polarization in the Tumor Microenvironment by Nanoparticles
Prof. Dr. rer. nat. Tobias Bopp, Professor for Molecular Immunology, Institute for Immunology, Johannes Gutenberg University Mainz (D)

Polymeric Nanoformulations to Promote Immunotherapy Responses
Dr. Lutz Nuhn, Junior Group Leader, Department of Prof. Tanja Weil, Max‐Planck‐Institute for Polymer Research (MPIP), Mainz (D)

The Effect of Glioblastoma Microenvironment on LocalImmune System: FDA Preparation of Clinically Suitable Nanobioconjugates
Prof. Dr. med. Julia Y. Ljubimova, Ph.D., Professor of Neurosurgery and Biomedical Sciences, Director of Nanomedicine Research Center, Department of Neurosurgery Oncology Translational Program, Samuel Oschin Comprehensive Cancer Center CEDARS-SINAI MEDICAL CENTER, Los Angeles, CA (USA)

Questions and Debate